Innate Pharma (IPHA) Debt to Equity (2017 - 2025)
Historic Debt to Equity for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $5.25.
- Innate Pharma's Debt to Equity rose 32618.3% to $5.25 in Q2 2025 from the same period last year, while for Jun 2025 it was $5.25, marking a year-over-year increase of 32618.3%. This contributed to the annual value of $3.51 for FY2024, which is 35647.11% up from last year.
- According to the latest figures from Q2 2025, Innate Pharma's Debt to Equity is $5.25, which was up 32618.3% from $3.51 recorded in Q4 2024.
- Over the past 5 years, Innate Pharma's Debt to Equity peaked at $5.25 during Q2 2025, and registered a low of $0.12 during Q2 2021.
- Moreover, its 5-year median value for Debt to Equity was $0.77 (2023), whereas its average is $1.46.
- As far as peak fluctuations go, Innate Pharma's Debt to Equity tumbled by 148.77% in 2023, and later skyrocketed by 35647.11% in 2024.
- Innate Pharma's Debt to Equity (Quarter) stood at $0.41 in 2021, then surged by 89.44% to $0.78 in 2022, then fell by 1.49% to $0.77 in 2023, then surged by 356.47% to $3.51 in 2024, then soared by 49.76% to $5.25 in 2025.
- Its Debt to Equity was $5.25 in Q2 2025, compared to $3.51 in Q4 2024 and $1.23 in Q2 2024.